R
Richard B. Kim
Researcher at University of Western Ontario
Publications - 380
Citations - 33088
Richard B. Kim is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 89, co-authored 328 publications receiving 30436 citations. Previous affiliations of Richard B. Kim include London Health Sciences Centre & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.
Markus Gulilat,Anthony Tang,Steven E. Gryn,Peter Leong-Sit,Allan C. Skanes,Jeffrey E. Alfonsi,George K. Dresser,Sara L. Henderson,Rhiannon V. Rose,Daniel J. Lizotte,Wendy A. Teft,Ute I. Schwarz,Rommel G. Tirona,Richard B. Kim +13 more
TL;DR: In this routine-care setting, rivaroxaban and apixaban plasma concentrations tended to be more variable than those observed in clinical trials, which may enable a more precise DOAC dosing regimen for the individual patient.
Journal ArticleDOI
In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism.
Gbenga G. Sofowora,Dishy,H. G. Xie,Imamura H,Nishimi Y,Morales Cr,Morrow Jd,Richard B. Kim,Charles M. Stein,Alastair J. J. Wood +9 more
TL;DR: It is concluded that in healthy volunteers the Glu298Asp polymorphism affects endogenous nitric oxide production without affectingNitric oxide-mediated vascular responses, and may only have clinical significance in the presence of endothelial dysfunction.
Journal ArticleDOI
Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling
Maria M. Posada,James A. Bacon,Karen B. Schneck,Rommel G. Tirona,Richard B. Kim,J. William Higgins,Y. Anne Pak,Stephen D. Hall,Kathleen M. Hillgren +8 more
TL;DR: The in vitro to in vivo extrapolation approach used in this work was developed to predict possible drug-drug interactions that may occur after coadministration of pemetrexed and nonsteroidal anti-inflammatory drugs (NSAIDs), and it included in vitro assays, risk assessment models, and physiologically based pharmacokinetic (PBPK) models.
Journal ArticleDOI
Targeted next generation sequencing as a tool for precision medicine
Markus Gulilat,Markus Gulilat,Tyler Lamb,Wendy A. Teft,Jian Wang,Jacqueline S. Dron,John F. Robinson,Rommel G. Tirona,Rommel G. Tirona,Robert A. Hegele,Richard B. Kim,Richard B. Kim,Ute I. Schwarz +12 more
TL;DR: PGxSeq can serve as a comprehensive, rapid, and reliable approach for the detection of common and novel SNVs in pharmacogenes benefiting the emerging field of precision medicine.
Journal ArticleDOI
Loss of RNA expression and allele-specific expression associated with congenital heart disease
David M. McKean,David M. McKean,Jason Homsy,Jason Homsy,Hiroko Wakimoto,Neil Patel,Joshua M. Gorham,Steven R. DePalma,Steven R. DePalma,James S. Ware,James S. Ware,James S. Ware,Samir Zaidi,Wenji Ma,Nihir Patel,Richard P. Lifton,Richard P. Lifton,Wendy K. Chung,Richard B. Kim,Yufeng Shen,Martina Brueckner,Elizabeth Goldmuntz,Andrew J. Sharp,Christine E. Seidman,Christine E. Seidman,Christine E. Seidman,Bruce D. Gelb,Jonathan G. Seidman +27 more
TL;DR: Compared with control subjects, CHD subjects have a significant burden of both LOE genes and ASE events associated with altered gene expression, and these studies identify FGFBP2, LBH, RBFOX2, SGSM1 and ZBTB16 as candidate CHD genes because of significantly altered transcriptional expression.